WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their VTGN stock forecasts and price targets.

Forecast return on equity

Is VTGN forecast to generate an efficient return?

Company
-306.93%
Industry
15.45%
Market
168.37%
VTGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VTGN forecast to generate an efficient return on assets?

Company
-210.26%
Industry
23.26%
VTGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VTGN earnings per share forecast

What is VTGN's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.50
Avg 2 year Forecast
-$1.57
Avg 3 year Forecast
-$1.69

VTGN revenue forecast

What is VTGN's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$969.0k-61.27%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$20.4M+715.35%
VTGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VTGN revenue growth forecast

How is VTGN forecast to perform vs Biotechnology companies and vs the US market?

Company
84.66%
Industry
32.77%
Market
13.34%
VTGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VTGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VTGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VTGN$0.24N/AN/A
GDTC$0.90N/AN/A
TOVX$0.23$1.00+334.78%Strong Buy
ASBP$7.82N/AN/A
OSRH$0.30N/AN/A
View Top Biotech Stocks

Vistagen Therapeutics Stock Forecast FAQ

What is VTGN's earnings growth forecast for 2027-2029?

(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.27%.

Vistagen Therapeutics's earnings in 2026 is -$67,620,000.On average, 7 Wall Street analysts forecast VTGN's earnings for 2027 to be -$66,765,063, with the lowest VTGN earnings forecast at -$65,234,059, and the highest VTGN earnings forecast at -$67,563,847. On average, 5 Wall Street analysts forecast VTGN's earnings for 2028 to be -$69,707,252, with the lowest VTGN earnings forecast at -$66,973,634, and the highest VTGN earnings forecast at -$71,757,465.

In 2029, VTGN is forecast to generate -$75,138,986 in earnings, with the lowest earnings forecast at -$72,192,359 and the highest earnings forecast at -$77,348,956.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.

What is VTGN's revenue growth forecast for 2027-2029?

(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual revenue growth rate of 84.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.34%.

Vistagen Therapeutics's revenue in 2026 is $2,502,000.On average, 5 Wall Street analysts forecast VTGN's revenue for 2027 to be $43,001,227, with the lowest VTGN revenue forecast at $0, and the highest VTGN revenue forecast at $88,531,937. On average, 4 Wall Street analysts forecast VTGN's revenue for 2028 to be $0, with the lowest VTGN revenue forecast at $0, and the highest VTGN revenue forecast at $0.

In 2029, VTGN is forecast to generate $905,288,984 in revenue, with the lowest revenue forecast at $869,787,456 and the highest revenue forecast at $931,915,131.

What is VTGN's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: VTGN) forecast ROA is -210.26%, which is lower than the forecast US Biotechnology industry average of 23.26%.

What is VTGN's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: VTGN) Vistagen Therapeutics's current Earnings Per Share (EPS) is -$1.66. On average, analysts forecast that VTGN's EPS will be -$1.50 for 2027, with the lowest EPS forecast at -$1.47, and the highest EPS forecast at -$1.52. On average, analysts forecast that VTGN's EPS will be -$1.57 for 2028, with the lowest EPS forecast at -$1.51, and the highest EPS forecast at -$1.62. In 2029, VTGN's EPS is forecast to hit -$1.69 (min: -$1.63, max: -$1.74).

What is VTGN's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: VTGN) forecast ROE is -306.93%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.